COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference
August 01, 2022 08:00 ET
|
COMPASS Pathways
LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
July 28, 2022 04:00 ET
|
COMPASS Pathways
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological...
COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
July 26, 2022 08:00 ET
|
COMPASS Pathways
LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
July 19, 2022 08:00 ET
|
COMPASS Pathways
Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsmith remains...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
May 23, 2022 07:00 ET
|
COMPASS Pathways
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...
COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference
May 12, 2022 08:00 ET
|
COMPASS Pathways
LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
May 10, 2022 07:00 ET
|
COMPASS Pathways
LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Highlights: End of phase II meeting held with FDAAward of Innovation Passport as part of the UK MHRA Innovative Licensing and Access...
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
May 09, 2022 07:00 ET
|
COMPASS Pathways
London, UK – 9 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today...
COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022
May 03, 2022 08:00 ET
|
COMPASS Pathways
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
May 03, 2022 07:00 ET
|
COMPASS Pathways
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022 COMPASS...